These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 34487441)

  • 1. Basal insulin plus GLP-1 RA or SGLT2 inhibitor was noninferior to basal-bolus insulin intensification for HbA
    Boggild MK; Cheung AM
    Ann Intern Med; 2021 Sep; 174(9):JC106. PubMed ID: 34487441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial.
    Giugliano D; Longo M; Caruso P; Di Fraia R; Scappaticcio L; Gicchino M; Petrizzo M; Bellastella G; Maiorino MI; Esposito K
    Diabetes Care; 2021 Jun; 44(6):1353-1360. PubMed ID: 33883195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In type 2 diabetes, GLP-1 RA plus SGLT2 inhibitor vs. either drug alone reduces HbA
    Tanner M
    Ann Intern Med; 2020 Nov; 173(10):JC52. PubMed ID: 33197349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simplification of complex insulin therapy: a story of dogma and therapeutic resignation.
    Giugliano D; Scappaticcio L; Longo M; Caruso P; Maiorino MI; Bellastella G; Esposito K
    Diabetes Res Clin Pract; 2021 Aug; 178():108958. PubMed ID: 34280468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis.
    Castellana M; Cignarelli A; Brescia F; Laviola L; Giorgino F
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3082. PubMed ID: 30270567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BEYOND 2 years: durability of metabolic benefits by simplification of complex insulin regimens in type 2 diabetes.
    Giugliano D; Longo M; Scappaticcio L; Caruso P; Gicchino M; Petrizzo M; Bellastella G; Maiorino MI; Esposito K
    Endocrine; 2024 Feb; 83(2):399-404. PubMed ID: 37787888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials.
    Porcellati F; Lucidi P; Bolli GB; Fanelli CG
    Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S16-6S20. PubMed ID: 26774015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
    Mantsiou C; Karagiannis T; Kakotrichi P; Malandris K; Avgerinos I; Liakos A; Tsapas A; Bekiari E
    Diabetes Obes Metab; 2020 Oct; 22(10):1857-1868. PubMed ID: 32476254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Optimizing basal insulin therapy in type 2 diabetes].
    Scheen AJ; Paquot N
    Rev Med Liege; 2017 Mar; 72(3):156-161. PubMed ID: 28387494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy.
    Goldenberg RM; Berard L
    Curr Med Res Opin; 2018 Jan; 34(1):1-10. PubMed ID: 28836861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
    Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
    Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?
    Darmon P; Raccah D
    Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S21-6S27. PubMed ID: 26774016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
    Zambrowicz B; Ding ZM; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Smith M; Ruff D; Sands A; Powell D
    Clin Ther; 2013 Mar; 35(3):273-285.e7. PubMed ID: 23433601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea.
    Lozano-Ortega G; Goring S; Bennett HA; Bergenheim K; Sternhufvud C; Mukherjee J
    Curr Med Res Opin; 2016 May; 32(5):807-16. PubMed ID: 26700585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification.
    Malek R; Ajili F; Assaad-Khalil SH; Shinde A; Chen JW; Van den Berg E
    Diabetes Metab; 2015 Jun; 41(3):223-30. PubMed ID: 25483023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospect of Sodium-Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes.
    Yang Y; Zhao C; Ye Y; Yu M; Qu X
    Front Endocrinol (Lausanne); 2020; 11():190. PubMed ID: 32351447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
    Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
    J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deintensification of basal-bolus insulin after initiation of GLP-1RA in patients with type 2 diabetes under routine care.
    Bonora BM; Rigato M; Frison V; D'Ambrosio M; Tadiotto F; Lapolla A; Simioni N; Paccagnella A; Avogaro A; Fadini GP
    Diabetes Res Clin Pract; 2021 Mar; 173():108686. PubMed ID: 33548335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes.
    Lundkvist P; Pereira MJ; Kamble PG; Katsogiannos P; Langkilde AM; Esterline R; Johnsson E; Eriksson JW
    J Clin Endocrinol Metab; 2019 Jan; 104(1):193-201. PubMed ID: 30137410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.